Summary
This 10-K filing for Johnson & Johnson for the fiscal year ended December 28, 2008, reflects the company's position as a large, diversified healthcare giant operating in a challenging economic environment. As a well-established issuer, JNJ maintained its standard reporting practices, detailing its business segments, risk factors, and financial performance. Investors should note the company's significant market capitalization and its ongoing commitment to research and development, crucial for maintaining its competitive edge in the pharmaceutical, medical devices, and consumer health sectors. The filing, while comprehensive, incorporates much of the detailed information through references to its Annual Report to Shareholders and Proxy Statement. This approach is typical for large companies and allows for a streamlined 10-K. Investors seeking a deeper understanding of the operational and financial intricacies should refer to these incorporated documents, particularly for detailed financial statements, management's discussion and analysis, and executive compensation.
Financial Highlights
52 data points| Revenue | $63.75B |
| Cost of Revenue | $18.51B |
| Gross Profit | $45.24B |
| SG&A Expenses | $21.49B |
| Interest Expense | $435.00M |
| Net Income | $12.95B |
| EPS (Basic) | $4.62 |
| EPS (Diluted) | $4.57 |
| Shares Outstanding (Basic) | 2.80B |
| Shares Outstanding (Diluted) | 2.84B |
Key Highlights
- 1Johnson & Johnson is a large accelerated filer, indicating a significant market capitalization (approximately $178 billion as of the last business day of the second fiscal quarter of 2008) and robust financial reporting history.
- 2The company operates across diversified business segments: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Care.
- 3The 10-K references extensive incorporated documents, including the Annual Report to Shareholders and Proxy Statement, which contain detailed financial statements and management's discussion.
- 4JNJ has a history of robust patent and trademark protection, essential for its product pipeline and market exclusivity.
- 5The company's business is subject to extensive regulation across all its operating segments, a key factor influencing its operations and strategic decisions.
- 6Research and Development (R&D) is highlighted as a critical function, signaling ongoing investment in innovation to maintain market leadership.
- 7The filing includes detailed information on various equity-based compensation plans for directors and executive officers, as well as severance arrangements.